Matthew J. Lazzara Matthew J. Lazzara, Ph.D.

Associate Professor of Chemical Engineering and Biomedical Engineering


Ph.D., MIT, 2003, Chemical Engineering
B.S., University of Florida, 1997, Chemical Engineering

Office: 310 Chemical Engineering Phone: 434-924-3428
Lab: B707 MR6 Phone: 434-982-2658

mlazzara@virginia.edu

 

   

Research Interests

Cell signaling is the biochemical process cells use to make decisions about virtually everything they do – migrate, differentiate, survive, die, and more. Signaling involves networks of intracellular proteins whose concentrations, post-translational modifications, or localization change in response to events such as receptor-ligand binding. Cells interpret these signaling network changes, using rules scientists are only beginning to decipher, to execute decision processes. While proper signaling is critical to normal development and health, aberrant signaling leads to numerous diseases, including cancer. Thus, the ability to engineer signaling processes or intervene effectively in aberrant signaling has huge medical implications. Our lab integrates experimental and computational methods to study fundamental aspects of cell signaling, including regulation by phosphatases and receptor trafficking, and applied aspects of cell signaling including the efficacy of therapeutics that target particular signaling pathways in cancer.

Selected Publications

Day EK, Sosale NG, and Lazzara MJ. Cell signaling regulation by protein phosphorylation: a multivariate, heterogeneous, and context-dependent process. Current Opinion in Biotechnology 40: 185-92, 2016.

Buonato JM, Lan IS, and Lazzara MJ. EGF augments TGFβ-induced epithelial-mesenchymal transition by promoting SHP2 binding to GAB1. Journal of Cell Science 128: 3898-909, 2015.

Furcht CM, Buonato JM, and Lazzara MJ. EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR. Science Signaling 8: ra46, 2015.

Walsh AM, Kapoor GS, Buonato JM, Mathew LK, Bi Y, Davuluri RV, Simon MC, O’Rourke DM, and Lazzara MJ. Sprouty2 drives drug resistance and proliferation in glioblastoma. Molecular Cancer Research 13: 1227-37, 2015.

Buonato JM and Lazzara MJ. ERK1/2 blockade prevents epithelial-mesenchymal transition and promotes cellular sensitivity to EGFR inhibition in lung cancer cells. Cancer Research 74: 309-319, 2014.